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ARTICLE
From karyotypes to precision genomics
in 9p deletion and duplication syndromes
Eleanor I. Sams,1 Jeffrey K. Ng,1 Victoria Tate,2 Ying-Chen Claire Hou,3 Yang Cao,3
Lucinda Antonacci-Fulton,4 Khadija Belhassan,3 Julie Neidich,2,3 Robi D. Mitra,1,4 F. Sessions Cole,2
Patricia Dickson,1,2 Jeffrey Milbrandt,1,4,5 and Tychele N. Turner1,*
While 9p deletion and duplication syndromes have been studied for several years, small sample sizes and minimal high-resolution data
have limited a comprehensive delineation of genotypic and phenotypic characteristics. In this study, we examined genetic data from 719
individuals in the worldwide 9p Network Cohort: a cohort seven to nine times larger than any previous study of 9p. Most breakpoints
occur in bands 9p22 and 9p24, accounting for 35% and 38% of all breakpoints, respectively. Bands 9p11 and 9p12 have the fewest breakpoints, with each accounting for 0.6% of all breakpoints. The most common phenotype in 9p deletion and duplication syndromes is
developmental delay, and we identified eight known neurodevelopmental disorder genes in 9p22 and 9p24. Since it has been previously
reported that some individuals have a secondary structural variant related to the 9p variant, we examined our cohort for these variants
and found 97 events. The top secondary variant involved 9q in 14 individuals (1.9%), including ring chromosomes and inversions. We
identified a gender bias with significant enrichment for females (p ¼ 0.0006) that may arise from a sex reversal in some individuals with
9p deletions. Genes on 9p were characterized regarding function, constraint metrics, and protein-protein interactions, resulting in a
prioritized set of genes for further study. Finally, we achieved precision genomics in one child with a complex 9p structural variation
using modern genomic technologies, demonstrating that long-read sequencing will be integral for some cases. Our study is the largest
ever on 9p-related syndromes and provides key insights into genetic factors involved in these syndromes.

Introduction
In this study, we focus on 9p deletion (MIM: 158170) (also
called 9p minus) and duplication syndromes,1,2 which arise
from a deletion or duplication involving the p arm of chromosome 9. There are several unresolved features of these syndromes due in part to low incidence and a lack of high-resolution genotype and phenotype data. We present the
largest-ever genomic assessment of 9p minus syndrome—
comprising of 719 individuals—and identify broad features
of this cohort. Through reviewing databases and the literature, we summarize phenotypic features of individuals
with 9p syndromes and characterize 9p genes and the proteins they encode. Finally, we present results of a study of
one child with a complex 9p structural variation assessed
by several modern genomic technologies including shortread whole-genome sequencing (WGS), long-read WGS,
and Bionano optical mapping. We compare these methods
with previous clinical tests for this individual (karyotype,
array, whole-exome sequencing) and show that long-read
sequencing is critical to achieving precision genomics. We
define precision genomics as ‘‘determining all possible relevant genomic variation within an individual to the precise
nucleotide.’’ This term is inspired by ‘‘precision medicine,’’
which is defined by President Barack Obama of the United
States of America as ‘‘health care tailored to you’’ with a
mission statement ‘‘to enable a new era of medicine through

research, technology, and policies that empower patients, researchers, and providers to work together toward development of individualized care’’ (https://obamawhitehouse.
archives.gov/precision-medicine). Ultimately, we want to
reach precision genomics to strengthen precision medicine
in syndromes arising from complex structural variations
including 9p deletion and duplication syndromes.
A critical aspect of human genetics and genomics is linking genotype to phenotype. In some diseases, it is clear what
gene is underlying the main phenotype (e.g., CFTR [MIM:
602421] in cystic fibrosis [MIM: 219700]3), while in other
cases it is not clear. Large, often complex structural variants
present a challenge because they can be recurrent with the
same breakpoints in all or most individuals (e.g., 22q11.2
[MIM: 192430], 16p11.2 [MIM: 611913],4,5 7q11.23 Williams syndrome region [MIM: 609757])6 or they can show
heterogeneity in breakpoints. Further, one gene can
underly the majority of the phenotype (e.g., RAI1 [MIM:
607642] in Smith-Magenis syndrome [MIM: 182290]) or
several genes can contribute to various phenotypes. 9p
deletion and duplication syndromes are particularly challenging because there is heterogeneity in breakpoint locations, they typically encompass several genes, and they
have variable phenotypes.
Analysis of different cohorts of individuals with 9p copynumber variants (CNVs) has established that the CNV
breakpoint locations are not consistent from patient to
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patient. This breakpoint variability is found when
comparing deletions with duplications as well as when
looking at each group independently. For example, one
cohort consisting of 65 individuals with 9p deletions
found 50 unique breakpoints with only 11 breakpoints
shared by at least two individuals.7 Studies comparing
the breakpoints of 9p deletions and duplications with
the presence of common 9p phenotypes in multiple cohorts have attempted to resolve the critical region for 9p
deletion and duplication syndromes.7–17 These studies
have suggested a deletion hotspot region within 9p22–
9p23,7–11 although individuals with typical 9p deletion
phenotypes and breakpoints outside this region have
been described.13,15 When including sex reversal (MIM:
154230) in the deletion syndrome, the proposed critical region extends to 9p24.3.17 The described 9p duplication
syndrome critical region occurs at 9p22.314,16; however,
individuals with a 9p duplication and less severe phenotypes typically have more proximal duplications occurring
between 9p12 and 9p22.1.16 Additionally, in approximately 50% of all cases of 9p minus syndrome, the affected
individual also has an associated translocation event, and
these translocations have not previously been preferentially linked to any specific chromosome.18 Beyond translocation events, even more complex variations including
ring chromosomes2 and mosaicism have also been
observed for some rearrangements and CNVs involving
9p19 as well as trisomy 9p mosaic syndrome.20,21 Understanding the exact nature of the variation is essential to
identify the genes affected by the variant and to link genotype to phenotype.
The most common phenotype that is seen in nearly
every individual with a 9p CNV is developmental delay
and intellectual disability (ID).8,18,22,23 Additional shared
phenotypes include hypotonia, low-set ears and abnormal
ear auricle, high/narrow palate, short/broad neck, broad
internipple distance, and the presence of a cardiac
murmur or defect.8,18,22 Some phenotypes observed in
individuals with 9p deletion and individuals with 9p
duplication appear to mirror each other,2 and some phenotypes are variations but not quite mirrors.8,18,22 Generally, the phenotypes in individuals with 9p CNVs are
quite variable8,18,22 depending on size and location of
the variants.12 An important phenotype to note that
often occurs in individuals with a 9p deletion is sex
reversal and other differences in sex development
(DSDs).8,12,13,17,24–30 Ambiguous genitalia are estimated
to be present in up to 70% of individuals with 9p deletion.27 The 46,XY sex reversal phenotype is more
commonly found in individuals with terminal 9p deletions than in those with more proximal deletions.17
Autism spectrum disorder (ASD) is another phenotype
that has been associated with 9p deletions and duplications. All ten individuals with 9p deletion described by
Hauge et al.12 were reported to display ASD or other
behavioral issues, and many additional 9p case reports
and cohorts include individuals with ASD.8,26,31–33 Com-
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parison of 9p CNV individuals with and without ASD
and the locations of their CNVs has led to the hypothesis
that there is an ASD candidate gene on 9p24.26,31,32
Despite the general genetic and phenotypic variability
seen in individuals with 9p deletions and duplications,
some progress has been made in associating common 9p
phenotypes with genes in the region. These candidates
include DMRT1 (MIM: 602424) and DMRT3 (MIM:
614754) in the DSD phenotype;17,27,29 FREM1 (MIM:
608944) implicated for trigonocephaly;19,34 FOXD4
(MIM: 601092) for speech and language deficits;12,19,26
DOCK8 (MIM: 611432) for IDs and seizure disorders that
are commonly seen in individuals with 9p CNVs;12,15,19,
29
GLDC (MIM: 238300),19 VLDLR (MIM: 192977),19 and
ZDHHC21 (MIM: 614605)10 for IDs and/or seizure disorders;19 and CBWD1 (MIM: 611078), which is associated
with cobalamin deficiency (feeding difficulties, failure to
thrive, hypotonia, seizures, microcephaly, ID, and developmental delay26). KANK1 (MIM: 607704) (previously
known as ANKRD15) displays what appears to be a
maternal imprinting mechanism in which inherited cerebral palsy can occur when the paternal copy of the gene
is disrupted.29,31 Applying precision genomics to 9p deletion and duplication syndromes can further refine these
genotype-phenotype associations and presents an opportunity to improve precision medicine in these syndromes.

Materials and methods
Assessment of 9p Network Cohort
De-identified data were accessed through the Chromosome 9p
Minus Network for 811 individuals. These data consist of details
of the 9p genomic variation, country of origin, and gender. Analyses of these characteristics were conducted using individuals
for which the relevant data were available. The genomic variation
data are on the level of broad genetic information (e.g., karyotype)
and are available for 719 individuals. Bands where the breakpoints
occurred for each individual were counted across the cohort. If
available, large structural changes on non-9p chromosome bands
were also counted in the subset of individuals. Sex chromosomes
are included in the broad genetic information for 236 individuals.

9p deletions and duplications from the literature
Genomic data were collected from the literature where approximate breakpoints are known for 53 individuals with 9p deletion
and duplication syndromes.12,14–17,19,27,29,30,33,35–48

Phenotype data from individuals with 9p deletion and
duplication syndromes
Phenotype data were collected from three papers8,18,22 assessing
individuals with 9p deletions (n ¼ 120 individuals) and one paper22 assessing individuals with 9p duplications (n ¼ 99 individuals). The phenotypes were categorized into the following 13 regions/systems: general, head, ears, nose, mouth, neck, thorax,
back, extremities, cardiovascular, respiratory, gastrointestinal,
and urogenital. Categories were then further defined into 38 specific phenotypes and aggregated into the percentage of individuals
with each phenotype in deletions and duplications, respectively.
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9p gene constraint and dosage characteristics
For each 9p gene, the pLI score was extracted from gnomAD.49
Dosage characteristics were pulled from a previous publication assessing 29,085 individuals with neurodevelopmental disorders
(NDDs) and 19,584 controls.50

Mappability on 9p and dosage of 9p in 1000 Genomes
Mappability tracks for 150-mers on build 38 of the human genome
were generated to determine the ability to map short-read Illumina
WGS data comprised of 150 base pair reads. The autosome and sex
chromosome sequences were extracted from the GRCh38_full_
analysis_set_plus_decoy_hla.fa reference file using samtools51
faidx, then the GEMtools52 (https://github.com/Chimera-tools/
ChimPipe.git) index was utilized to index the genome, and finally,
gem-mappability was used to perform the mappability analysis.
The output file was converted from the gem mappability file to a
wig and then converted to a bigwig file (https://data.cyverse.org/
dav-anon/iplant/home/turnerlabwashu/Turner_Lab_Track_Hubs/
genomic_annotations/GRCh38_mappability_150mer.bw). CNV
across 9p in the 1000 Genomes Project data was visualized in the
UCSC genome browser53 using data from a previous publication54 available at https://github.com/KiddLab/kmer_1KG.

Known 9p gene/phenotype associations
The 435 RefSeq genes on 9p were assessed for their association
with known phenotypes by running them through GeneALaCart55 (https://genealacart.genecards.org/). Genes with an elite
association were extracted from the file and underwent manual
curation via a literature review. The disease associations
were then broadly assigned into the following categories:
NDD, neurodegenerative, cancer, skeletal, immune, sex reversal,
eye, diabetes, obesity, albinism, kidney, premature menopause/
ovarian failure, muscle, arthrogryposis, head, mouth, and
blood.

genomes/all/GCA/009/914/755/GCA_009914755.3_CHM13_T2T_
v1.1/GCA_009914755.3_CHM13_T2T_v1.1_genomic.fna.gz) was
also performed on the Illumina data. Bionano optical mapping was
carried out as described previously.33 PacBio HiFi long-read
sequencing was performed to a coverage depth of 46.12 for individual 9p.100.p1. The CCS fastq files were aligned to build 38 of the human genome (GRCh38_full_analysis_set_plus_decoy_hla.fa) using
pbmm2 (https://github.com/PacificBiosciences/pbmm2) v.1.3.0
align. PacBio pbsv (https://github.com/PacificBiosciences/pbsv) v.
2.3.0 was used to call copy-number and structural variants. Readdepth profiles were also generated using mosdepth.60 DeepVariant58 v. 1.0.0, using model PACBIO, was used to generate SNV/indel
GVCF files for each individual, and they were joint-genotyped using
GLNexus v.1.2.7. De novo assemblies were generated using two
different assemblers (HiCanu [Canu v.2.0]61 and Hifiasm62 v.0.13r307) for each individual.
PCR and Sanger sequencing were performed for the regions
on both ends of the rearrangement between chromosome X
and chromosome 9 in 9p.100.p1. Primers were designed using
Primer3Plus (https://primer3plus.com) to target both rearrangement breakpoint regions, for a total of two amplicons. PCR reactions were performed using the primers, genomic DNA from
9p.100.p1, and Thermo Scientific Phusion High-Fidelity PCR
Master Mix with HF Buffer. The two PCR products then underwent PCR cleanup and Sanger sequencing through Genewiz
(https://www.genewiz.com). Each product was sequenced in
both the forward and reverse directions, for a total of four
sequencing products. Sequencing results were obtained
from fasta files and aligned to the GRCh38 reference genome using the BLAST-like alignment tool (BLAT) from the UCSC
genome browser (https://genome.ucsc.edu). BLAT alignments
were further examined to confirm the rearrangement
breakpoints.

Results
Protein-protein interactions on 9p
A STRINGdb56 (https://string-db.org/) analysis was performed using all of the 9p protein-coding genes.

Genomic assessment of 9p.100.p1
Family 9p.100 consists of an unaffected father (9p.100.fa), an
unaffected mother (9p.100.mo), and a male child (9p.100.p1)
with 9p deletion and duplication syndrome. The child has
global developmental delays, hypotonia, joint hypermobility,
and immunodeficiency. He has no significant family history.
Previous clinical tests include a karyotype, microarray, and
whole-exome sequencing. In this study, we assessed individual
9p.100.p1 by Illumina short-read WGS, Bionano optical mapping, and Pacific Biosciences (PacBio) HiFi long-read WGS. Individuals 9p.100.fa and 9p.100.mo were also assessed by PacBio
HiFi long-read WGS.
Illumina WGS was performed to a coverage depth of 59.93 for
individual 9p.100.p1. Reads were mapped to GRCh38_full_analysis_
set_plus_decoy_hla.fa using bwa57 mem v.0.7.10-r789. Single-nucleotide variants (SNVs) and small insertion/deletions (indels) were detected using DeepVariant58 v.1.0.0 using WGS as the model and
default settings. CNV was detected using the QuicK-mer254 program
with GRCh38 as the reference genome. The steps included running
quicKmer2 count followed by quicKmer2 est. An additional QuicKmer2 analysis using the new Telomere-to-Telomere (T2T) consortium reference genome file59 (https://ftp.ncbi.nlm.nih.gov/

Insights from the worldwide 9p Network Cohort
There are 811 individuals (Table S1) in the 9p Network
Cohort dataset from 59 different countries representing
six continents (Figure 1A). The dataset has low-resolution
genetic information for 719 individuals with structural
variants involving 9p and is seven to nine times bigger
than the largest previously studied cohorts of 9p deletion18 or duplication22 syndromes. Although the genetic
information for this cohort is low resolution, the large
sample size allows us to investigate broader patterns of
structural variants involving 9p.
In the 9p Network Cohort, we found that the greatest
number of breakpoints are located in the chromosome
bands 9p24 and 9p22, with 257 (38.1%) and 233 (34.6%)
of the 674 total breakpoints listed in the dataset, respectively (Figure 1B). The least common chromosome bands
for 9p breakpoints are 9p12 and 9p11, each with 4
(0.6%) of the total breakpoints in the dataset. These patterns are consistent with the proposed 9p24 and 9p22 critical regions as well as with trends in breakpoint locations
in previously published cases (Figure S1). We aggregated
data from published cases and the 9p Network Cohort dataset to investigate which chromosome arms are most
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Figure 1. Characteristics of 9p network cohort
(A) Global location of individuals in the 9p Network Cohort. Countries represented by at least one individual in the 9p Network Cohort
are highlighted in blue. All 811 individuals in the 9p Network Cohort were used to construct the map.
(B) Chromosome band breakpoints of 9p Network Cohort CNVs. The bar plot displays the number and percentage of breakpoints within
each chromosome sub-band for CNVs listed in the 9p Network Cohort. Breakpoints are grouped by sub-band to remain consistent with
the resolution of breakpoints reported in the 9p Network Cohort.
(C) Other chromosome arms affected in individuals with 9p CNVs. The number and percentage of events involving other chromosome
arms in individuals with a 9p CNV are shown. Events include deletions, duplications, translocations, and inversions and seven individuals with ring chromosome 9 (dark blue stripes).

commonly involved in secondary structural variants in individuals with 9p deletion and duplication syndromes.
This analysis revealed that 9q has the highest number of
secondary events, due in part to ring chromosome 9
(Figure 1C). Other frequently affected chromosome arms
include 1q, 8q, and 11q.
In addition to genetic data, the 9p Network Cohort
dataset also lists the gender for all 719 individuals. Of
these individuals, 406 individuals are female and 313
are male, indicating a female bias (Binomial test p ¼
0.0006). This result was surprising considering that no female bias has been previously reported in 9p deletion and
duplication syndromes. A possible explanation for the
significant bias in the 9p Network Cohort dataset is the
XY sex reversal phenotype, which is commonly observed
in individuals with 9p deletion syndrome. This phenotype could lead to individuals with XY sex chromosomes
being listed in the dataset as having a female gender. To
further examine this hypothesis, we subset our dataset
to include only the 236 individuals whose sex chromosomes are listed in their genetic information. For this
much smaller subset, 125 individuals had female sex
chromosomes and 111 had male sex chromosomes, indicating no significant sex bias (Binomial test p ¼ 0.4). We
also found no significant gender bias in this group (Binomial test p ¼ 0.2), although we did confirm that four of
the individuals with XY sex chromosomes had a gender
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of female. This comparison suggests that the XY sex
reversal phenotype may be responsible for a female
gender bias, but not a sex bias, in 9p deletion and duplication syndrome cohorts.
Phenotypic characteristics of individuals with 9p
deletions and duplications
Since we did not have phenotype information for the 9p
Network Cohort, a literature search was performed to characterize common phenotypes in 9p deletion and duplication syndromes (Table 1). From this meta-analysis of 219 individuals, the most frequently observed phenotype is
developmental delay (100% in deletions, 99% in duplications). There are nine shared phenotypes between individuals with a deletion or duplication including developmental delays (100% in deletions, 99% in duplications),
hypotonia (65.7% in deletions, 61.8% in duplications),
low-set ears (85.1% in deletions, 67.1% in duplications),
abnormal auricles (51% in deletions, 83.1% in duplications), high/narrow palates (87.7% in deletions, 62.2% in
duplications), short/broad necks (93.7% in deletions,
68.8% in duplications), broad internipple distances
(92.3% in deletions, 44% in duplications), single palmar
crease (69.8% in deletions, 90.6% in duplications), and cardiac murmurs/deficits (48.6% in deletions, 26.7% in duplications). There are also mirrored phenotypes including upward slanting palpebral fissures in deletions and downward
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Table 1.

Summary of 9p deletion and duplication syndrome phenotypic workups with more than 25 individuals
Publications studying individuals
with deletions (percentage of
individuals with phenotype)

Publication studying individuals
with duplications (percent of
individuals with phenotype)

Region/system
affected

Specific phenotype

Swinkels et al.8 Huret et al.18
and Young et al.22 (n ¼ 120)

Young et al.22 (n ¼ 99)

Phenotype
comparisons
of deletions
and
duplications

General

developmental delay

100.0

99.0

shared

speech delay

100.0

NA

motor delay

100.0

NA

hypotonia

65.7

61.8

trigonocephaly

84.3

NA

midface hypoplasia

82.4

NA

upward slanting palpebral fissures

63.2

NA

mirror

downward slanting
palpebral fissures

15.0

61.2

mirror

Head

Ears

Nose

Mouth

shared

short palpebral fissures

88.5

NA

epicanthal fold

65.6

NA

high, arched eyebrows

60.0

NA

amblyopia

33.3

NA

low-set

85.1

67.1

shared

abnormal auricle

51.0

83.1

shared

posteriorly angulated

45.5

NA

small (<p3)

40.0

NA

short/flat

85.1

NA

anteverted nostrils

88.7

NA

thin upper lip

92.3

NA

long philtrum

93.1

NA

mirror

flat philtrum

46.2

NA

high/narrow palate

87.7

62.2

irregular teeth

30.0

NA

micro/retrognathia

77.3

NA

Neck

short/broad

93.7

68.8

shared

Thorax

broad internipple distance

92.3

44.0

shared

Back

scoliosis

41.2

NA

Extremities

tapering fingers

63.6

NA

single palmar crease

69.8

90.6

hyperconvex nails

66.7

NA

flat feet

72.7

NA

hyperlax joints

50.0

NA

Cardiovascular

cardiac murmur/deficit

48.6

26.7

Respiratory

frequent colds/infections

81.8

NA

Gastrointestinal

inguinal hernia

27.7

NA

omphalocele

15.4

NA

renal abnormalities

7.7

NA

abnormal genitals

36.7

NA

Urogenital

shared

shared

shared

NA, not available.
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Figure 2. 9p Genes with an associated disease/disorder
The genome browser view shows 9p genes with a manually curated disorder/disease association according to MalaCards. Genes are
broadly categorized based on the general region/system affected and are more specifically grouped within each category. Specific groups
within each category are indicated by different colors as follows: blood: all ¼ black; brain: NDD ¼ red, neurodegenerative ¼ blue; cancer:
all ¼ black; head: general ¼ black, eyes ¼ red, eyes/general ¼ blue, mouth/general ¼ gold, eyes/mouth ¼ gray; immune system: all ¼
black; musculoskeletal: skeletal ¼ red, muscle ¼ blue; urogenital: infertility ¼ black, sex reversal ¼ red, premature menopause/ovarian
failure ¼ blue, kidney ¼ gold; other: arthrogryposis ¼ black, diabetes ¼ red, obesity ¼ blue, albinism ¼ gold. NDD, neurodevelopmental
disorder.

slanting palpebral fissures in duplications as well as
long philtrum in deletions and short philtrum in
duplications.
Characteristics of genes on the p arm of chromosome 9
We examined the 435 RefSeq genes on 9p for constraint and
dosage features (Table S2). There were 27 constrained genes
(BNC2 [MIM: 608669]; CDC37L1 [MIM: 610346]; CLTA
[MIM: 118960]; CNTFR [MIM: 118946]; ELAVL2 [MIM:
601673]; MLLT3 [MIM: 159558]; NFIB [MIM: 600728];
NOL6 [MIM: 611532]; PAX5 [MIM: 167414]; PSIP1 [MIM:
603620]; PTPRD [MIM: 601598]; RFX3 [MIM: 601337];
RNF38 [MIM: 612488]; RPS6 [MIM: 180460]; RUSC2
[MIM: 611053]; SHB [MIM: 600314]; SMARCA2 [MIM:
600014]; SMU1 [MIM: 617811]; TAF1L [MIM: 607798];
TEK [MIM: 600221]; TESK1 [MIM: 601782]; TLN1 [MIM:
186745]; TOPORS [MIM: 609507]; UBAP1 [MIM: 609787];
UBE2R2 [MIM: 612506]; UHRF2 [MIM: 615211]; and VCP
[MIM: 611745]) with a pLI >0.9, which indicates that dominant disruption of these genes may have phenotypic consequences. We note here that a pLI >0.9 may be too restrictive

6

when considering recessive disruption and that a different
pLI cutoff could be considered for recessive genes in the
future. This will be possible to explore further with precision genomics in 9p deletion and duplication syndromes.
To further understand these genes and potential phenotypic consequences, we looked for enrichment of deletions
or duplications in a dataset of 29,085 individuals with
NDDs and 19,584 controls.50 Six of the pLI >0.9 genes
were enriched for deletions in individuals with NDDs
(CDC37L1, NFIB, PTPRD, RFX3, SMARCA2, UHRF2), and
all 27 were enriched for duplications in individuals with
NDDs (BNC2, CDC37L1, CLTA, CNTFR, ELAVL2, MLLT3,
NFIB, NOL6, PAX5, PSIP1, PTPRD, RFX3, RNF38, RPS6,
RUSC2, SHB, SMARCA2, SMU1, TAF1L, TEK, TESK1, TLN1,
TOPORS, UBAP1, UBE2R2, UHRF2, VCP). This observation
suggests that the dosage of these genes may play a role in
NDDs. The mappability of most of 9p is quite high for
short-read WGS data, indicating that the detection of
CNV should be robust (Figure S2). Copy-number assessments generated from short-read WGS data in individuals
from the 1000 Genomes Project54 reveal that the copy
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Figure 3. Protein-protein interaction analysis of chromosome arms
(A) The bar plot shows the ratio of observed edges (interactions) versus expected interactions between proteins from genes on each chromosome arm (p < 1.0 3 1016). Chromosome arms with a ratio of zero did not have enough data to perform the analysis. The p arm of
chromosome 9 (boxed in red) shows the highest observed versus expected interaction ratio.
(B) The interaction network for proteins from 9p is shown. Note that there is a cluster of interactions between the IFNA (interferon) proteins, which are involved in immune system function.

number of the majority of 9p is not variable in the population (Figure S2).
To expand beyond NDDs, a search for other gene/disease
associations was carried out (Table S3; Figure 2). This analysis
revealed two genes in blood phenotypes (JAK2 [MIM:
147796], B4GALT1 [MIM: 137060]); 17 genes in NDDs
(KANK1, SMARCA2, VLDLR, SLC1A1 [MIM: 133550], RIC1
[MIM: 610354], GLDC, MPDZ [MIM: 603785], NFIB,
ADAMTSL1 [MIM: 609198], PLAA [MIM: 603873], IFT74
[MIM: 608040], B4GALT1, GALT [MIM: 606999], PIGO
[MIM: 614730], RUSC2, GNE [MIM: 603824], EXOSC3
[MIM: 606489]); five genes in neurodegenerative disorders
(C9ORF72 [MIM: 614260], APTX [MIM: 606350], MYORG
[MIM: 618255], SIGMAR1 [MIM: 601978], VCP); eight genes
in cancer (JAK2, MLLT3, MIR31 [MIM: 612155], MTAP [MIM:
156540], CDKN2A [MIM: 600160], CDKN2B [MIM: 600431],
FANCG [MIM: 602956], PAX5); eight genes in head-related
phenotypes (KCNV2 [MIM: 607604], FREM1, ADAMTSL1,
TEK, DDX58 [MIM: 609631], TOPORS, B4GALT1, IL11RA
[MIM: 600939]); three genes in immune phenotypes
(DOCK8, DOCK8-AS1, RMRP [MIM: 157660]); nine genes
in musculoskeletal phenotypes (KLHL9 [MIM: 611201],
DDX58, UBAP1, SIGMAR1, TPM2 [MIM: 190990], GBA2
[MIM: 609471], NPR2 [MIM: 607072], GNE, RMRP); ten
genes in urogenital phenotypes (DMRT1, DMRT2 [MIM:
604935], SLC1A1, FREM1, BNC2, ADAMTSL1, TEK, DNAI1
[MIM: 604366], GALT, GRHPR [MIM: 604296]); and four
genes involved in other phenotypes (GLIS3 [MIM: 610192],
a gene known to exhibit imprinting, GLDC, TYRP1 [MIM:
115501], TPM2). Importantly, 29 of these genes are known
to be involved in autosomal recessive conditions, including
DNAI1 in primary ciliary dyskinesia and GALT in galactosemia. Fourteen of these autosomal recessive genes are asso-

ciated with neurological phenotypes (e.g., KANK1 in cerebral
palsy and MPDZ in congenital hydrocephalus), which may
contribute to atypical or severe NDD phenotypes in some
patients with 9p CNVs. Disruption of these genes can thus
potentially unmask recessive traits and contribute to phenotypic variability and should be explored in patients with
complex presentations.
We performed a STRINGdb56 analysis using all of the 9p
protein-coding genes (n ¼ 207) to better understand the
degree of interaction between the proteins encoded by
genes on 9p. There were 57 expected edges (interactions)
between the proteins, and we found that there are 177
observed interactions between the 207 proteins from 9p,
indicating an observed-versus-expected ratio of 3.11. This
represents a significant enrichment of interactions between proteins on 9p (p < 1.0 3 1016) (Figure 3A). The
interaction network driving this enrichment involves the
IFNA genes (Figure 3B). These interferon genes are clustered together on 9p and are involved in immune function. We also looked at the observed-versus-expected interactions between proteins on every other chromosome arm.
Some chromosome arms were not able to be assessed using
this approach due to a lack of gene density on the arm
(13p, 14p, 15p, 21p, 22p, Yp, Yq). We observed that the
level of interaction enrichment was the highest for 9p
(Figure 3A).
Precision genomics for 9p.100.p1
Several genomic technologies were utilized to determine
which could fully resolve the structural variation in an individual (9p.100.p1) with a complex structural variation on 9p
(Figure 4). Previous clinical karyotype testing identified a
large 9p deletion and a translocation of chromosome 14
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Figure 4. Precision genomics for
9p.100.p1
(A) Summary of structural variations and
resolutions using different genomic technologies.
(B) Schematic of structural variations
related to 9p in the individual.
(C) In the left panel, the copy-number estimates are shown for the p arm of chromosome 9 and identify a large deletion followed by a mosaic duplication. In the
right panel, a zoom-in of the region near
the telomere of chromosome 9p is shown
to harbor a small deletion followed by a
diploid segment and then a small part of
the large deletion.
(D) Shown is the resolved variations,
including orientation, for the small
diploid segment on the telomeric end of
9p. This was resolved using a de novo assembly built with long-read sequencing.

A

B

C

D

on the chromosome 9 containing the deletion (Figure 4A).
Prior clinical microarray analysis identified a large 9p deletion and a mosaic 9p duplication (Figure 4A). The final clinical test was whole-exome sequencing, which identified a
large 9p deletion (Figure 4A). Three newer genomic technologies were utilized in this study to gather additional data (Illumina short-read WGS, Bionano optical mapping, and PacBio HiFi long-read WGS) (Figure 4A). Bionano optical
mapping was the least informative because this technology
does not provide actual sequence data, so we instead focused
primarily on the final resolution of the complex variation
through the use of short-read and long-read WGS (Figures
4A and 4B).
The estimated copy number was calculated across the
genome using short-read WGS, which revealed a large deletion and a mosaic duplication on chromosome 9
(Figure 4C). Attempts at finding the expected translocation
breakpoint involving chromosomes 9 and 14, known from
karyotype analysis, instead revealed a breakpoint involving

8

chromosomes 9 and X. A deeper examination of the estimated copy number
near the telomere on chromosome 9
found a small deletion followed by a
segment with copy number 2 followed
by the large deletion (Figure 4C). The
exact base pairs at the border of this
diploid region could not be determined
using short-read WGS. To explore this
variation further, the de novo assembly
built from long-read WGS was queried
to look for the sequences in the diploid
segment (see Figure S3 for details on
assembly comparisons). A contig
was identified that revealed that one
copy of this segment was on the X
chromosome (Figure 4D), and Sanger
sequencing confirmed the rearrangement breakpoints. The expected structure for the
chromosomes 9 and X rearrangement in 9p.100.p1 involves
an insertion of the region chr9:135,780–272,997 at
chrX:106,377,425. Importantly, the chromosome 9 region
is inverted relative to the chromosome X sequence. The
BLAT alignment for the first PCR product covers
chrX:106,377,216–106,377,425 and chr9:272,759–272,998,
and the alignment of the reverse product for this
region covers chrX:106,377,193–106,377,425 and chr9:
272,797–272,998. The BLAT alignment for the forward product of the second rearrangement breakpoint covers
chrX:106,377,430–106,377,786 and chr9:135,779–136,
055, and the reverse product alignment covers chrX:
106,377,430–106,377,744 and chr9:135,779–136,090. These
alignments support the expected rearrangement coordinates
and directionality. To summarize, the minimal technologies
needed to resolve all variations in this individual (i.e., precision genomics) were a karyotype to find the 9/14 translocation since chromosome 14 had no large dosage changes,
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either microarray or short-read WGS to find the mosaic 9p
duplication, and long-read WGS to find the complex variation near the telomere on chromosome 9.
Since the field is moving toward using newer reference
genomes (i.e., T2T genome59), copy-number estimates
from short-read WGS were also assessed using T2T reference, and the overall results were the same (Figure S4). A
query of the sequence at breakpoints derived by longread WGS was also compared with the T2T reference
genome, and there was a slight shift of coordinates, as expected, when comparing any two genome builds
(Figure S4). Overall, the comparison with T2T may be useful for resolving variations in some individuals in the
future but did not change the overall interpretation for
this individual.
With the precise variation determined for 9p.100.p1, the
genes located within each variant were identified (Table 2).
Important genes within the variant regions include
DOCK8, implicated in immune phenotypes, and DOCK8,
GLDC, KANK1, VLDLR, and MPDZ, implicated in NDDs.
Other genes of interest include CDC37L1, PTPRD, RFX3,
SMARCA2, and UHRF2, which all have a pLI >0.9 and are
enriched for deletions/duplications in individuals with
NDDs (Table 2). As a research study, we are also working
on the process of reporting research results back to participants who would like access to the detailed genomic information. A concise one-page report was determined to be the
best strategy for relaying the precision genomics research
results. This report (Figure S5) clearly notes that this is a
research report and has three main features: a schematic
of the variation, a table of the precise breakpoints, and a
table of the genes affected in each of the variant regions
on chromosome 9. This approach could be a template for
other research studies involving complex structural
variations.

Discussion
In this study, we present an analysis of the largest cohort of
individuals with 9p deletions and duplications studied to
date. We first assessed the genomic variation in this cohort
to determine if there are any trends in the 9p breakpoint region and confirmed 9p22 and 9p24 as the regions with the
most breakpoints, as previously described in studies seven
to nine times smaller than the present study. We then assessed the genomic variations to determine if there were
any trends in the chromosome arms involved in secondary
structural variations. A similar investigation of structural
variation patterns in other phenotypes and syndromes
has proven crucial to improving clinical management and
developing therapeutic applications. For example, many
cases of chronic myeloid leukemia (CML) are driven by a
fusion protein derived from a translocation between chromosomes 9 and 22 (MIM: 608232). Importantly, identification of this variation pattern, known as ‘‘The Philadelphia
Chromosome,’’63 has enabled successful targeting by clin-

ical therapeutics (MIM: 608232). In contrast to The Philadelphia Chromosome and CML, we found that the pattern
of breakpoints and chromosome arms affected by secondary structural variants in 9p deletion and duplication syndromes is more heterogeneous. This reinforces the genetic
and clinical complexities of these syndromes and the
need for a precision genomics approach.
While DSDs have been reported in 9p deletion and
duplication syndromes, we identify for the first time a significant gender bias in the full cohort with an enrichment
for females. Among those with available sex chromosome
information, we found individuals in the cohort with a
gender of female and a sex chromosome complement of
XY as expected in some DSDs. To make this a comprehensive study of phenotypes and genes in 9p deletion and
duplication syndromes, we performed a meta-analysis of
phenotypes observed in 9p deletion and duplication syndromes and found shared, similar, mirrored, and differing
phenotypes. Several gene features were also considered for
prioritization including constraint, enrichment for deletions/duplications in NDDs, and prior established disease
associations. These are useful resources for the assessment
of 9p-related structural variations. Recently developed
genomic technologies are revolutionizing the way we
assess syndromes with complex structural variations. We
applied several of these technologies in this study to an individual with a complex 9p deletion, duplication, and
associated translocation. We found that the classical karyotype is essential, that either a microarray or short-read
WGS is critical to identify the mosaic duplication, and
that long-read sequencing is the only technology able to
resolve the intricate complexities of this variation.
The early studies of 9p deletion and duplication syndromes relied on the use of karyotyping,1 which does not
have the resolution to define CNV breakpoints beyond
the chromosome band and can fail to detect microdeletions and microduplications.26 The absence of high-resolution alignments and precise breakpoint analysis is one factor that has contributed to the difficulty in establishing
genotype-phenotype correlations with 9p CNVs.9,64 The
advancements of modern sequencing technologies provide an opportunity to precisely resolve breakpoints to
the exact base,33 thus allowing for a better characterization
of 9p CNVs both in terms of genomic variation and phenotypes. The power of long-read sequencing technologies
(e.g., Oxford Nanopore Technologies and PacBio) is
enabling complete genomic variant resolution within individuals,65,66 as shown in the present study. In addition,
advancing the bioinformatic assessment of long-read
sequencing data is also providing insight into methylation
and will be useful for examining imprinted genes on 9p.67
These types of technologies will be critical to the growing
understanding of 9p CNVs, especially when many affected
individuals present with complex rearrangements.
Another recent use of modern high-resolution sequencing
technologies by Ng et al.33 for a patient with a complex rearrangement involving a 9p deletion and a 13q duplication
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Table 2.

Genes involved in the structural variation identified in 9p.100.p1

Variant

Gene names

9p- deletion1

CBWD1, DDX11L5,
FAM138C, FOXD4,
MIR1302-9, PGM5P3AS1, WASHC1

9p piece with one
copy now on the X
chromosome, overall
diploid

CBWD1, DOCK8,
DOCK8-AS1

9p- deletion2

AK3, CD274,
CDC37L1, CDC37L1DT, DMAC1, DMRT1,
DMRT2, DMRT3,
DOCK8, ERMP1,
GLDC, GLIS3, GLIS3AS1, IL33, INSL4,
INSL6, JAK2, KANK1,
KCNV2, KDM4C,
KIAA2026,
LINC01230,
LINC01231, MIR1012, MIR4665, MLANA,
PDCD1LG2, PLGRKT,
PLPP6, PTPRD,
PTPRD-AS1, PUM3,
RANBP6, RCL1, RFX3,
RFX3-AS1, RIC1,
RLN1, RLN2, SLC1A1,
SMARCA2, SPATA6L,
TPD52L3, UHRF2,
VLDLR, VLDLR-AS1

9p- mosaic
duplication

PTPRD,
LOC105375972,
PTPRD-AS2, TYRP1,
LURAP1L-AS1,
LURAP1L, SNORD137,
MPDZ

Variation notes

both the CBWD1 and
DOCK8 genes are
broken even though
this full piece of DNA
is diploid and moved
to the X chromosome

of the genes in the
region,
LOC105375972,
PTPRD-AS2, TYRP1,
LURAP1L-AS1,
LURAP1L, SNORD137,
and MPDZ are fully
duplicated

Genes implicated as
having a possible 9p
phenotype

Genes with deletion
nominal
enrichment in NDDs

Genes with
duplication nominal
enrichment in NDDs

Genes with
pLI > 0.9

Genes with known
phenotype
(category)

FOXD4 (speech and
language
development)

None

none

none

none

DOCK8 (ID, seizures,
autism)

DOCK8

none

none

DOCK8 (immune)

KANK1 (cerebral
palsy), DMRT3
(disorders of sex
development),
DMRT1 (disorders of
sex development),
GLDC (intellectual
disability, seizures),
DOCK8 (intellectual
disability, seizures,
autism), VLDLR
(intellectual disability,
seizures, cerebellar
hypoplasia/ataxia)

AK3, CD274,
CDC37L1, CDC37L1DT, DMAC1, DMRT1,
DMRT2, DMRT3,
DOCK8, DOCK8-AS1,
ERMP1, GLDC, GLIS3,
GLIS3-AS1, IL33,
INSL4, INSL6, JAK2,
KANK1, KCNV2,
KDM4C, KIAA2026,
LINC01230,
LINC01231, MIR1012, MIR4665, MLANA,
PDCD1LG2, PLGRKT,
PLPP6, PTPRD,
PTPRD-AS1, PTPRDAS2, PUM3, RANBP6,
RCL1, RFX3, RFX3AS1, RIC1, RLN1,
RLN2, SLC1A1,
SMARCA2, SPATA6L,
TPD52L3, UHRF2,
VLDLR, VLDLR-AS1

AK3, CD274,
CDC37L1, CDC37L1DT, DMAC1, DMRT1,
DMRT2, DMRT3,
ERMP1, GLDC, GLIS3,
GLIS3-AS1, IL33,
INSL4, INSL6, JAK2,
KANK1, KCNV2,
KDM4C, KIAA2026,
LINC01230,
LINC01231, MIR1012, MIR4665, MLANA,
PDCD1LG2, PLGRKT,
PLPP6, PTPRD,
PTPRD-AS1, PTPRDAS2, PUM3, RANBP6,
RCL1, RFX3, RFX3AS1, RIC1, RLN1,
RLN2, SLC1A1,
SMARCA2, SPATA6L,
TPD52L3, UHRF2,
VLDLR, VLDLR-AS1

CDC37L1, PTPRD,
RFX3, SMARCA2,
UHRF2

DMRT1 (sex reversal),
DMRT3 (sex reversal),
DOCK8 (immune),
DOCK8-AS1
(immune), GLDC
(NDD, obesity), GLIS3
(diabetes), JAK2
(cancer), KANK1
(NDD), KCNV2 (eye),
SLC1A1 (kidney,
NDD), SMARCA2
(NDD), VLDLR (NDD)

PTPRD,
LOC105375972,
PTPRD-AS2, TYRP1,
LURAP1L, LURAP1LAS1, SNORD137,
MPDZ

PTPRD,
LOC105375972,
PTPRD-AS2, TYRP1,
LURAP1L, LURAP1LAS1, SNORD137,
MPDZ

PTPRD

TYRP1 (albinism),
MPDZ (NDD)

that translocated onto the chromosome 9 containing the
deletion allowed for the resolution of breakpoints to the
single-nucleotide level.33 Analysis of single-nucleotide resolution breakpoints provides the ability to precisely resolve
the genomic region associated with patient phenotypes
and ultimately identify genes affected by the genomic
variation.
Another area for future development is the linking of genotypes with phenotypes in individuals with 9p deletion
and duplication syndromes. Many approaches can be utilized including critical region delineation. However, we
also highlight the application of machine learning to complex biological problems and suggest it as a strategy to
combine all of the genomic and phenotypic data. The
application of novel genomic technologies with deep phenotyping on a large cohort of individuals would be the
ideal input to these types of models.
Considerable progress has been made in the assessment
of 9p deletion and duplication syndromes. However, it is
still challenging to predict an affected individual’s phenotypes with the currently available data. Part of this phenotypic unpredictability is attributable to the low genomic
resolution possible with older genotyping methods. Current technological advances in genomics are providing
strategies to detect all forms of variations in the genome
at a large scale and a reasonable cost. For example, in 9p
deletion syndrome, these technologies can identify the
precise breakpoints of the event, detect potentially relevant variations on the remaining allele, and look at the
remainder of the genome for other relevant events (e.g.,
a second hit). Utilizing this information across many individuals with 9p deletion and duplication syndromes and
combining it with leading edge analyses of phenotypic
data (e.g., the parsing of electronic health records) will
enable the delineation of complete genotype-phenotype
correlations. This combined work will bring the dream of
precision genomics to reality in 9p deletion and duplication syndromes.
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L., Pérez-Cabrera, A., Gonzalez-Huerta, L.M., Guevara-Yañez,
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SUPPLEMENTAL FIGURE LEGENDS
Figure S1: Genome Browser View of 9p CNVs. The genome browser view encompasses the
p arm of chromosome 9 (top). 9p deletions (red) and duplications (blue) are shown for 53
individuals with previously published breakpoint coordinates (bottom). The paper or the Coriell
database (https://www.coriell.org/1/NIGMS/Collections/Chromosomal-Abnormalities) from which
the data were obtained is also listed on the diagram.
Figure S2: Genome Browser View of Copy Number Estimates in 1000 Genomes and
Mappability on 9p. Shown are the range of copy number estimates in populations from the 1000
Genomes Project49 (AFR = African, AMR = Ad Mixed American, EAS = East Asian, EUR =
European, SAS = South Asian). At the bottom of the browser is the visualization of the mappability
for 150 mers where the higher values indicate better mappability.
Figure S3: Assembly Characteristics for 9p.100.p1 Using HiCanu and Hifiasm. A) Four
different HiCanu de novo assemblies (one SMRT cell, two SMRT cells, three SMRT cells, four
SMRT cells) are characterized in this figure. The NG values are shown for each assembly and
show the best gains in NG size at three SMRT cells. B) Four different Hifiasm de novo assemblies
(one SMRT cell, two SMRT cells, three SMRT cells, four SMRT cells) are characterized in this
figure. The NG values are shown for each assembly and show the best gains in NG size at two
SMRT cells
Figure S4: Comparison of Copy Number Assessment Using GRCh38 Versus T2T Reference
Genomes. A) Copy number estimates on 9p using GRCh38 as the reference (top) and T2T as
the reference (bottom). B) Copy number estimates on a zoom in region on the telomeric portion
of 9p using GRCh38 as the reference (top) and T2T as the reference (bottom). C) de novo
assembly resolution of complex 9p variation using GRCh38 as the reference (top) and T2T as the
reference (bottom).

Figure S5: Example 9p Project Research Report. Shown is a project report for 9p.100.p1. This
report summarizes in one page the complete resolution of the 9p variation in this individual.
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